| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2019: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2017: ¥7,280,000 (Direct Cost: ¥5,600,000、Indirect Cost: ¥1,680,000)
|
|---|
| Outline of Final Research Achievements |
Comparative genome analysis between early-stage and late stage lung cancers made us realize the following things. 1) Mutational signatures predominant in the early-stage lung cancers are not smoking related; DNA adduct formation by unspecified factors other than smoking drive mutagenesis in tumor initiation. 2) Early-stage lung cancer have frequent driver oncogene mutations, such as EGFR mutations, but infrequent TP53 and chromatin regulating gene mutations; Tumor initiation has occurred, but, these tumors have not yet genetically acquired progressive properties, such as tumor invasiveness, genome instability and tolerance to oncogene stress.
|
